AIM listed Venn Life Sciences (LON:VENN) CEO, Tony Richardson, tells Proactive Investors that he expects the solid first half momentum to continue, driven in part by strong demand from Biotechnology companies. He also sees increasing opportunities from medical device companies and mid sized pharmaceutical companies.Venn Life has a solid pipeline of potential opportunities which could be worth up to 18 million Euros. The company provides outsourced clinical contract research services and has recently been winning bigger contracts and taking on more staff. Richardson also sees acquisition opportunities in Central and Eastern Europe.
Venn Life Sciences riding the Biotech wave
Quick facts: Open Orphan PLC
Price: 16 GBX
Market Cap: £87.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE